RT Journal Article
SR Electronic
T1 Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.18.21251504
DO 10.1101/2021.02.18.21251504
A1 Salina, Ana C. G.
A1 dos-Santos, Douglas
A1 Rodrigues, Tamara S.
A1 Fortes-Rocha, Marlon
A1 Freitas-Filho, Edismauro G.
A1 Alzamora-Terrel, Daniel L.
A1 Castro, Ícaro M. S.
A1 Fraga da Silva, Thais F. C.
A1 de Lima, Mikhael H. F.
A1 Nascimento, Daniele C.
A1 Silva, Camila M.
A1 Toller-Kawahisa, Juliana E.
A1 Becerra, Amanda
A1 Oliveira, Samuel
A1 Caetité, Diego B.
A1 Almeida, Leticia
A1 Ishimoto, Adriene Y.
A1 Lima, Thais M.
A1 Martins, Ronaldo B.
A1 Veras, Flavio
A1 do Amaral, Natália B.
A1 Giannini, Marcela C.
A1 Bonjorno, Letícia P.
A1 Lopes, Maria I. F.
A1 Benatti, Maira N.
A1 Batah, Sabrina S.
A1 Santana, Rodrigo C.
A1 Vilar, Fernando C.
A1 Martins, Maria A.
A1 Assad, Rodrigo L.
A1 de Almeida, Sergio C. L.
A1 de Oliveira, Fabiola R.
A1 Neto, Eurico Arruda
A1 Cunha, Thiago M.
A1 Alves-Filho, José C.
A1 Bonato, Vânia L. D.
A1 Cunha, Fernando Q.
A1 Fabro, Alexandre T.
A1 Nakaya, Helder I.
A1 Zamboni, Dario S.
A1 Louzada-Junior, Paulo
A1 Oliveira, Rene D. R.
A1 Cunha, Larissa D.
YR 2022
UL http://medrxiv.org/content/early/2022/04/27/2021.02.18.21251504.abstract
AB COVID-19 is a disease of dysfunctional immune responses, but the mechanisms triggering immunopathogenesis are not established. The functional plasticity of macrophages allows this cell type to promote pathogen elimination and inflammation or suppress inflammation and promote tissue remodeling and injury repair. During an infection, the clearance of dead and dying cells, a process named efferocytosis, can modulate the interplay between these contrasting functions. Here, we show that engulfment of SARS-CoV2-infected apoptotic cells exacerbates inflammatory cytokine production, inhibits the expression of efferocytic receptors, and impairs continual efferocytosis by macrophages. We also provide evidence supporting that lung monocytes and macrophages from severe COVID-19 patients have compromised efferocytic capacity. Our findings reveal that dysfunctional efferocytosis of SARS-CoV-2-infected cell corpses suppress macrophage anti-inflammation and efficient tissue repair programs and provide mechanistic insights for the excessive production of pro-inflammatory cytokines and accumulation of tissue damage associated with COVID-19 immunopathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) grants 2018/25559-4 and 2020/05288-6 (L.D.C) Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) grant 88887.507253/2020-00 (D. S. Z. and L.D.C.) Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) grant 434538/2018-3 (L.D.C.) D.S., A. C. G. S., T. S. R. are supported by FAPESP fellowships. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The procedures followed in the study were approved by the Research Ethics Committee of Hospital das Clinicas de Ribeirao Preto (CEP-FMRP/USP) and by the National Ethics Committee, Brazil (Comissao Nacional de Etica em Pesquisa (CONEP), protocols 30248420.9.0000.5440 and 39722020.9.0000.5440.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther information and requests for data should be directed to and will be fulfillled by the Lead Contact, Larissa D. Cunha